6,700 Shares in Pulse Biosciences (PLSE) Purchased by Ladenburg Thalmann Financial Services Inc.

Ladenburg Thalmann Financial Services Inc. bought a new stake in Pulse Biosciences (NASDAQ:PLSE) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 6,700 shares of the company’s stock, valued at approximately $158,000.

A number of other institutional investors also recently modified their holdings of the business. The Manufacturers Life Insurance Company increased its holdings in Pulse Biosciences by 1,785.0% in the fourth quarter. The Manufacturers Life Insurance Company now owns 7,295 shares of the company’s stock valued at $172,000 after buying an additional 6,908 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Pulse Biosciences by 13.8% in the 3rd quarter. Wells Fargo & Company MN now owns 61,398 shares of the company’s stock valued at $1,143,000 after purchasing an additional 7,465 shares during the last quarter. Brown Advisory Inc. acquired a new position in shares of Pulse Biosciences in the 4th quarter valued at $248,000. Alliancebernstein L.P. acquired a new position in shares of Pulse Biosciences in the 4th quarter valued at $248,000. Finally, Deutsche Bank AG boosted its holdings in shares of Pulse Biosciences by 141.3% in the 4th quarter. Deutsche Bank AG now owns 20,305 shares of the company’s stock valued at $478,000 after purchasing an additional 11,890 shares during the last quarter. 10.84% of the stock is owned by institutional investors.

How to Become a New Pot Stock Millionaire

Shares of PLSE stock opened at $20.10 on Friday. Pulse Biosciences has a 52 week low of $9.81 and a 52 week high of $39.50.

Pulse Biosciences (NASDAQ:PLSE) last issued its earnings results on Friday, March 16th. The company reported ($0.53) EPS for the quarter.

A number of equities analysts have recently commented on the stock. BidaskClub raised shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. ValuEngine raised shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st.

TRADEMARK VIOLATION NOTICE: “6,700 Shares in Pulse Biosciences (PLSE) Purchased by Ladenburg Thalmann Financial Services Inc.” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/15/6700-shares-in-pulse-biosciences-plse-purchased-by-ladenburg-thalmann-financial-services-inc.html.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc, a clinical-stage medical technology company, develops therapeutic tissue treatment platform based on its proprietary nano-pulse stimulation (NPS) technology. Its NPS is a non-thermal, precise, and focal drug-free tissue treatment technology that initiates cell death within treated tissue used in oncology, dermatology/aesthetics, minimally invasive, and veterinary applications.

Want to see what other hedge funds are holding PLSE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pulse Biosciences (NASDAQ:PLSE).

Institutional Ownership by Quarter for Pulse Biosciences (NASDAQ:PLSE)

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply